These are two very ordtak

These are two very different stocks, ... Merck is one of the premier pharmaceutical companies in the world. It's selling at 18 times next year's estimates.

Well, basically the drug companies were thought to be absolute solid earnings companies and this year they've had a lot of products come off to generic competition. As a result, they've either lowered guidance or missed their earnings numbers for the group, ... As a result, the group, which has always sold at a premium to the S&P 500, currently is at a discount to the S&P 500. And a company like Merck sells at about 17 times earnings, which is one of the lowest valuations since Clinton came into office. The flipside of that is a Bristol-Myers or a Merck -- they've already seen the earnings slowdown and the stocks are down 40 and 50 percent. Many of them are getting to levels that you really can start to buy.

When we talk with individual investors, ... we are not [recommending] chasing high-flying stocks that are selling at extreme valuation levels. Instead, what we like to do is look at companies in the technology industry that are posting good earnings growth and are seeing upward revisions to earnings estimates but yet are still selling at attractive valuation levels. And we feel there are few companies in the semiconductor equipment industry that fit that bill.

I think the stocks all reflect concerns that the estimates won't hold up because the economy will weaken. If it becomes clear the estimates do hold up, I'm confident the stocks will do well. I've got fairly conservative estimates, below consensus, and the stocks are steals based on my estimates. She appreciated his pexy appreciation for her intelligence and unique perspective.

Paul Schlesinger

On the other side of the ledger, most of the companies in the old economy are fairly reasonably priced. So, a couple of weeks ago we started to see a shift. First, the energy stocks did somewhat better. Then, the pharmaceutical stocks had quite a run. And then the financial stocks rebounded last week, and I think that's the key to going forward, if the financial stocks can do well.

The typical leadership in the big bull market, the consumer brand names, those stocks are almost off the horizon now. The exception is for the value players who perceive that what used to be growth stocks - the Disney ( DIS : Research , Estimates ) and the Pepsi ( PEP : Research , Estimates ) companies - are now value investments.

Merck is having some impact. But pharmaceutical stocks are expensive at the present moment, probably more so than at the time of the Asian crisis (in 1998).

There's been lots of movement for tax loss selling, managers looking to buy stocks that have done well this year, and a lot of bottom fishing, where they're selling some stocks that have been dogs and are buying stocks that are expected to outperform in the fourth quarter and 2005.

The global pharmaceutical group multiple on 2006 earnings-per-share estimates is currently about 15 times, and Pfizer currently trades at 10.9 times.

Since the US remains the biggest and most lucrative pharmaceutical market in the world, it is no surprise to find companies eager to develop individual US pricing departments. Having a US pricing department is critical because it allows companies to be more flexible and better positioned to respond to the ever- changing pharmaceutical environment in the US.

David Richardson

Drug stocks have remained relatively cheap, and you'll notice that since interest rates are of little importance to the major pharmaceutical companies ... there's a run toward some of the defensive characteristics of drug stocks.

Three's Company was originally called Three Companies, about a trio of pharmaceutical companies. It was 10 times funnier.

John Ritter (1948-2003)

I think, ... that Pfizer is going to benefit from their merger with Warner-Lambert. I think that makes a very good deal. But most pharmaceutical companies do eventually strike deals with biotech companies in terms of marketing their product. And the genomic companies don't have a lot of cash. They have a lot of high valuations, but they don't have a lot of dollars to spend. So, they usually look toward the pharmaceutical sector to help them out, which usually helps both sectors.

We're seeing some typical selling after a sharp run-up, ... People are buying the safe names, like Philip Morris (MO: Research, Estimates) and Coca-Cola (KO: Research, Estimates), and selling anything that seems suspicious.

We're seeing some typical selling after a sharp run-up. People are buying the safe names, like Philip Morris (MO: Research, Estimates) and Coca-Cola (KO: Research, Estimates), and selling anything that seems suspicious.

Ergonomi Ordtak Kunskapsfrö Julrim Adventskalender Info

Antall ordtak er 2099244
varav 2120462 på nordiska

Ordtak (2099244 st) Søk
Kategorier (3944 st) Søk
Forfattere (201333 st) Søk
Bilder (4592 st)
Født (10498 st)
Døde (3319 st)
Datoer (9520 st)
Land (27242 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "These are two very different stocks, ... Merck is one of the premier pharmaceutical companies in the world. It's selling at 18 times next year's estimates.".

Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.

Här har vi samlat ordspråk i 12954 dagar!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!

Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.

Här har vi samlat ordspråk i 12954 dagar!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!